歐洲蛋白質體學市場（按產品、應用和國家分類）分析與預測（2024 年至 2034 年）

預計歐洲蛋白質體學市場規模將從 2024 年的 87.7 億美元成長到 2034 年的 274.3 億美元，2024-2034 年預測期間的複合年成長率為 12.07%。

質譜和次世代定序技術的進步使得蛋白質分析越來越準確，推動了歐洲蛋白質體學市場的成長。此外，由於人們努力發現新的生物標記和改善疾病分析，個人化醫療活動不斷增加，因此需求也在增加。歐盟計畫的強大研究資金、日益成長的官民合作關係以及醫院、生物技術公司和學術界之間的戰略聯盟正在推動新興蛋白質組學應用的發展。同時，歐洲人口老化和慢性病的增加凸顯了對更好的診斷和早期檢測技術的需求，使得蛋白質體學成為該地區臨床創新和生命科學研發環境的關鍵組成部分。

市場介紹

隨著越來越多的臨床研究機構、製藥公司和生命科學研究人員意識到分析蛋白質水平有助於了解疾病原因、發現生物標記並加速藥物開發，歐洲蛋白質組學市場正在快速成長。在高解析度質譜、微流體樣品製備和先進生物資訊學不斷進步的推動下，區域供應商和服務供應商正在引入整合系統，以最佳化從樣品輸入到數據解釋的工作流程。透過公共和私人資金流（從國家研究項目到地平線歐洲基金）加速腫瘤學、免疫學和神經退化領域的轉化計劃，推動了對發現規模和有針對性的蛋白質組學解決方案的需求。

透過改善對尖端單細胞和空間蛋白質組學技術的獲取，產學研合作和聯盟使研究人員能夠繪製組織微環境中的細胞異質性圖並確定新的治療標靶。臨床實驗室正在逐步檢驗多反應監測試驗和無標定定量方法，用於伴隨診斷和患者分層，為更廣泛的監管核准和報銷奠定基礎。透過對核心設施和數據分析技能的基礎設施投資，蛋白質體學已牢固確立為西歐和北歐以及新興的東歐中心個性化和精準醫療議程的關鍵組成部分。

展望未來，市場參與者期望通訊協定進一步標準化，多組體學資料流之間的互通性得到改善，並擴大與雲端處理供應商的合作，以降低進入門檻並為疫苗開發、生物標記檢驗和即時治療效果相關人員開闢新的途徑。

歐洲蛋白質體學市場趨勢、促進因素與挑戰

趨勢

• 高解析度質譜儀與單細胞和空間蛋白質組學工作流程的整合度不斷提高
• 擴展蛋白質體學、基因組學和代謝體學相結合的多體學學平台
• 擴大採用無標定定量和數據獨立採集來實現更深入的蛋白質組覆蓋
• 雲端基礎的生物資訊學和人工智慧主導的數據分析流程的出現
• 標靶蛋白質體學 (PRM/MRM) 在臨床檢測開發的應用日益廣泛

驅動程式

• 強大的歐盟和國家資助計劃，支持生物標記的發現和轉化研究
• 對精準醫療解決方案的需求，包括伴隨診斷和分層患者照護
• 產學合作和聯盟的發展加速了技術檢驗
• 藥物開發中高級安全性和有效性測試的監管激勵措施
• 改善早期疾病檢測和治療反應監測的壓力

任務

• 最先進的設備和專業人員的資本和營運成本高昂
• 複雜的樣品製備工作流程與實驗室間的差異
• 龐大的蛋白質體學資料集和缺乏統一的標準造成了資料管理瓶頸
• 蛋白質體學診斷的臨床驗證和監管途徑有限
• 需要建立強大的品管架構和實驗室間可重複性研究

產品/創新策略：歐洲蛋白質體學市場大致按產品、應用和國家等不同類別細分。這有助於讀者清楚地了解哪個部分佔有最大佔有率以及哪個部分在未來幾年可能會成長。

競爭策略：歐洲蛋白質體學市場有許多現有參與者，擁有自己的產品和服務組合。本研究分析和介紹的歐洲蛋白質體學市場的主要企業概況包括提供蛋白質體學產品和服務的知名公司。

主要市場參與企業及競爭格局

所介紹的公司是根據從頂尖專家收集的資訊、分析公司的覆蓋範圍、類型組合和市場滲透率而選出的。

本報告研究了歐洲蛋白質體學市場，概述了市場，詳細介紹了產品、應用和國家趨勢，以及參與市場的公司概況。

目錄

執行摘要

第1章 市場

• 市場展望
• 主要發現
• 歐洲蛋白質體學市場概況
• 產業展望
  • 供應鏈概覽
• 趨勢：現況與未來影響評估
  • 推進端到端蛋白質體學工作流程的自動化
  • 市場參與企業之間的眾多合作
  • 擴大蛋白質體學研究以識別疾病生物標記
• 專利分析
  • 專利申請趨勢（按國家和年份）
• 法律規範
  • 歐洲聯盟
• 產品基準
• 市場動態概覽
  • 市場促進因素
  • 市場限制
  • 市場機會

2. 蛋白質體學市場（按地區分類），百萬美元，2022-2034 年

• 區域摘要
• 歐洲
  • 區域概況
  • 市場成長動力
  • 成長抑制因素
  • 歐洲蛋白質體學市場應用狀況
  • 歐洲蛋白質體學市場（按產品提供）
  • 法國
  • 義大利
  • 德國
  • 英國
  • 西班牙
  • 其他

第3章 市場競爭基準化分析與公司概況

• 蛋白質體學市場：競爭格局
  • 企業策略 2022 年 1 月 - 2024 年 12 月
  • 夥伴關係、聯盟和業務擴展
  • 合併與收購
  • 新服務
• 公司簡介
  • Biognosys AG
  • DiaSorin SpA
  • Merck KGaA
  • Oxford Expression Technologies Ltd.

第4章調查方法

Introduction to Europe Proteomics Market

The Europe proteomics market is projected to reach $27.43 billion by 2034 from $8.77 billion in 2024, growing at a CAGR of 12.07% during the forecast period 2024-2034. Advances in mass spectrometry and next-generation sequencing technologies, which provide ever-increasing precision in protein analysis, are driving the proteomics market's growth in Europe. Demand is further increased by a rise in personalised healthcare activities, which are fuelled by initiatives to find new biomarkers and improve disease profiling. New proteomic applications are being accelerated by strong research funding from EU programs, expanding public-private partnerships, and strategic alliances between hospitals, biotech companies, and academia. In the meantime, Europe's ageing population and increasing prevalence of chronic diseases highlight the need for better diagnostics and early detection techniques, solidifying proteomics as a key component of the region's clinical innovation and life-science R&D environment.

Market Introduction

The market for proteomics in Europe is growing rapidly as more and more clinical labs, pharmaceutical companies, and life science researchers realise how effective protein-level analysis is in understanding disease causes, finding biomarkers, and speeding up drug development. Regional vendors and service providers are launching integrated systems that optimise workflows from sample input to data interpretation, driven by ongoing advancements in high-resolution mass spectrometry, microfluidic sample preparation, and advanced bioinformatics. The need for both discovery-scale and targeted proteomics solutions is being driven by the acceleration of translational projects in oncology, immunology, and neurodegeneration through public and private funding streams, ranging from national research efforts to Horizon Europe funds.

By increasing access to state-of-the-art single-cell and spatial proteomics techniques, academic-industry clinicpartnerships and consortia have made it possible for researchers to map cellular heterogeneity within tissue microenvironments and identify new therapeutic targets. Clinical laboratories are laying the groundwork for wider regulatory approval and reimbursement by progressively validating multiple response monitoring assays and label-free quantification for companion diagnostics and patient stratification. Infrastructure investments in core facilities and data-analysis skills are solidifying proteomics as a key component of personalised and precision medicine plans throughout Western Europe, the Nordics, and rising Eastern European hubs.

In the future, market players expect that further standardisation of protocols, improved interoperability between multi-omics data streams, and expanding collaborations with cloud computing providers will reduce entry barriers and open up new avenues for vaccine development, biomarker validation, and real-time therapeutic efficacy monitoring.

Market Segmentation

Segmentation 1: by Offering

• Product
• Service

Segmentation 2: by Application

• Drug Discovery
• Clinical Diagnostics
• Others

Segmentation 3: by Region

• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Proteomics Market Trends, Drivers and Challenges

Trends

• Growing integration of high-resolution mass spectrometers with single-cell and spatial proteomics workflows
• Expansion of multi-omics platforms combining proteomics with genomics and metabolomics
• Increased adoption of label-free quantitation and data-independent acquisition for deeper proteome coverage
• Emergence of cloud-based bioinformatics and AI-driven data analysis pipelines
• Rising use of targeted proteomics (PRM/MRM) in clinical assay development

Drivers

• Strong EU and national funding programmes supporting biomarker discovery and translational research
• Demand for precision medicine solutions, including companion diagnostics and stratified patient care
• Growth of academic-industry partnerships and consortia accelerating technology validation
• Regulatory encouragement for advanced safety and efficacy testing in drug development
• Pressure to improve early-stage disease detection and monitor therapeutic responses

Challenges

• High capital and operational costs for state-of-the-art instrumentation and specialized personnel
• Complex sample preparation workflows and variability across laboratories
• Data management bottlenecks due to massive proteomic datasets and lack of harmonized standards
• Limited clinical validation and regulatory pathways for proteomics-based diagnostics
• Need for robust quality-control frameworks and inter-laboratory reproducibility studies

How can this report add value to an organization?

Product/Innovation Strategy: The Europe proteomics market has been extensively segmented based on various categories, such as offering, application, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe proteomics market has numerous established players with product and service portfolios. Key players in the Europe proteomics market analyzed and profiled in the study involve established players offering proteomics products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.

Some prominent names in the Europe proteomics market include:

• Biognosys AG
• DiaSorin S.p.A.
• Merck KGaA

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Outlook
  • 1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
  • 1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations
• 1.2 Key Findings
• 1.3 Europe Proteomics Market Scenario
  • 1.3.1 Realistic Scenario
  • 1.3.2 Optimistic Scenario
  • 1.3.3 Pessimistic Scenario
• 1.4 Industry Outlook
  • 1.4.1 Supply Chain Overview
• 1.5 Trends: Current and Future Impact Assessment
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Significant Number of Collaborations among Market Players
  • 1.5.3 Growing Proteomics Research to Identify Disease Biomarkers
• 1.6 Patent Analysis
  • 1.6.1 Patent Filing Trend (by Country, Year)
• 1.7 Regulatory Framework
  • 1.7.1 European Union (EU)
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.1.1.1 EU Medical Device Regulation
      • 1.7.1.1.2 EU In Vitro Diagnostic Regulation
    • 1.7.1.2 Regulatory Requirements for Clinical Proteomics Labs in the EU
• 1.8 Product Benchmarking
• 1.9 Market Dynamics Overview
  • 1.9.1 Market Drivers
    • 1.9.1.1 Increasing Prevalence of Chronic Diseases
    • 1.9.1.2 Increasing Technological Advancements
    • 1.9.1.3 Advancements in Personalized Medicine and Drug Discovery
  • 1.9.2 Market Restraints
    • 1.9.2.1 Shortage of Skilled Professionals
    • 1.9.2.2 Complexity in Analyzing Data of Proteomics Research
  • 1.9.3 Market Opportunities
    • 1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes

2 Proteomics Market (by Region), $Million, 2022-2034

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Europe Proteomics Market, by Application
  • 2.2.5 Europe Proteomics Market, by Offering
    • 2.2.5.1 Europe Proteomics Market, by Product
  • 2.2.6 France
    • 2.2.6.1 France Proteomics Market, by Application
    • 2.2.6.2 France Proteomics Market, by Offering
      • 2.2.6.2.1 France Proteomics Market, by Product
  • 2.2.7 Italy
    • 2.2.7.1 Italy Proteomics Market, by Application
    • 2.2.7.2 Italy Proteomics Market, by Offering
      • 2.2.7.2.1 Italy Proteomics Market, by Product
  • 2.2.8 Germany
    • 2.2.8.1 Germany Proteomics Market, by Application
    • 2.2.8.2 Germany Proteomics Market, by Offering
      • 2.2.8.2.1 Germany Proteomics Market, by Product
  • 2.2.9 U.K.
    • 2.2.9.1 U.K. Proteomics Market, by Application
    • 2.2.9.2 U.K. Proteomics Market, by Offering
      • 2.2.9.2.1 U.K. Proteomics Market, by Product
  • 2.2.10 Spain
    • 2.2.10.1 Spain Proteomics Market, by Application
    • 2.2.10.2 Spain Proteomics Market, by Offering
      • 2.2.10.2.1 Spain Proteomics Market, by Product
  • 2.2.11 Rest-of-Europe
    • 2.2.11.1 Rest-of-Europe Proteomics Market, by Application
    • 2.2.11.2 Rest-of-Europe Proteomics Market, by Offering
      • 2.2.11.2.1 Rest-of-Europe Proteomics Market, by Product

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Proteomics Market: Competitive Landscape
  • 3.1.1 Corporate Strategies, January 2022-December 2024
  • 3.1.2 Partnerships, Alliances, and Business Expansions
  • 3.1.3 Mergers and Acquisitions
  • 3.1.4 New Offerings
• 3.2 Company Profiles
  • 3.2.1 Biognosys AG
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products/ Services
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 DiaSorin S.p.A.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/ Services
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Merck KGaA
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/ Services
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Oxford Expression Technologies Ltd.
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/ Services
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Proteomics Market (by Application), $Billion, 2022, 2027, and 2034
• Figure 2: Europe Proteomics Market (by Product), $Billion, 2022, 2027, and 2034
• Figure 3: Key Events to Keep Track of within the Proteomics Market
• Figure 4: Europe Proteomics Market Size, $Billion, 2022-2034
• Figure 5: Proteomics Literature Published (January 2015 to December 2024)
• Figure 6: Europe Proteomics Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2034
• Figure 7: Europe Proteomics Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022 to 2034
• Figure 8: Europe Proteomics Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022 to 2034
• Figure 9: Supply Chain and Risks within the Supply Chain
• Figure 10: Key Features of End-to-End Proteomics Workflow
• Figure 11: Proteomics Market, Patent Analysis (by Country), January 2021-December 2024
• Figure 12: Proteomics Market, Patent Analysis (by Year), January 2021-December 2024
• Figure 13: Proteomics Market, Product Benchmarking (by Product)
• Figure 14: Impact Analysis of Market Navigating Factors, 2024-2034
• Figure 15: Timeline on the Personalized Medicine Journey of Protein
• Figure 16: Difficulties Faced in Top-Down Proteomics
• Figure 17: Future Outlook of Nanoproteomics
• Figure 18: Europe Proteomics Market, $Billion, 2022-2034
• Figure 19: Proteomics Literature Published in Canada (January 2015 to December 2024)
• Figure 20: France Proteomics Market, $Billion, 2022-2034
• Figure 21: Proteomics Literature Published in Italy (January 2015 to December 2024)
• Figure 22: Italy Proteomics Market, $Billion, 2022-2034
• Figure 23: Proteomics Literature Published in Germany (January 2015 to December 2024)
• Figure 24: Germany Proteomics Market, $Billion, 2022-2034
• Figure 25: Proteomics Literature Published in the U.K. (January 2015 to December 2024)
• Figure 26: U.K. Proteomics Market, $Billion, 2022-2034
• Figure 27: Proteomics Literature Published in Spain (January 2015 to December 2024)
• Figure 28: Spain Proteomics Market, $Billion, 2022-2034
• Figure 29: Rest-of-Europe Proteomics Market, $Billion, 2022-2034
• Figure 30: Corporate Strategies, January 2022-December 2024
• Figure 31: Acquisitions (by Company), January 2022-December 2024
• Figure 32: New Offerings Share (by Company), January 2022-December 2024
• Figure 33: Data Triangulation
• Figure 34: Top-Down and Bottom-Up Approach
• Figure 35: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: The Diversified Exposure of Proteomics
• Table 4: Comparative Analysis of Proteomics: Advantages and Disadvantages Over Other Omics Approaches
• Table 5: Introduction to Proteomics Techniques: Principles, Advantages, and Limitations
• Table 6: Comparison of Existing and Emerging Paradigms in Proteomics Technologies
• Table 7: Proteomics Market Trend Analysis
• Table 8: Some of the Partnerships and Collaborations in the Proteomics Market
• Table 9: List of Molecular Targets Identified with Proteomics
• Table 10: Cancer Cases Expected Between 2020 and 2040
• Table 11: Proteomics Market, Regulatory Approvals, and New Offerings
• Table 12: Cancer Biomarkers Discovered by Proteomics and its Applications in Personalized Medicine
• Table 13: Proteomics Market (by Region), $Billion, 2022-2034
• Table 14: Europe Proteomics Market (by Application), $Billion, 2022-2034
• Table 15: Europe Proteomics Market (by Offering), $Billion, 2022-2034
• Table 16: Europe Proteomics Market (by Product), $Billion, 2022-2034
• Table 17: France Proteomics Market (by Application), $Billion, 2022-2034
• Table 18: France Proteomics Market (by Offering), $Billion, 2022-2034
• Table 19: France Proteomics Market (by Product), $Billion, 2022-2034
• Table 20: Italy Proteomics Market (by Application), $Billion, 2022-2034
• Table 21: Italy Proteomics Market (by Offering), $Billion, 2022-2034
• Table 22: Italy Proteomics Market (by Product), $Billion, 2022-2034
• Table 23: Germany Proteomics Market (by Application), $Billion, 2022-2034
• Table 24: Germany Proteomics Market (by Offering), $Billion, 2022-2034
• Table 25: Germany Proteomics Market (by Product), $Billion, 2022-2034
• Table 26: U.K. Proteomics Market (by Application), $Billion, 2022-2034
• Table 27: U.K. Proteomics Market (by Offering), $Billion, 2022-2034
• Table 28: U.K. Proteomics Market (by Product), $Billion, 2022-2034
• Table 29: Spain Proteomics Market (by Application), $Billion, 2022-2034
• Table 30: Spain Proteomics Market (by Offering), $Billion, 2022-2034
• Table 31: Spain Proteomics Market (by Product), $Billion, 2022-2034
• Table 32: Rest-of-Europe Proteomics Market (by Application), $Billion, 2022-2034
• Table 33: Rest-of-Europe Proteomics Market (by Offering), $Billion, 2022-2034
• Table 34: Rest-of-Europe Proteomics Market (by Product), $Billion, 2022-2034
• Table 35: Partnerships, Alliances, and Business Expansions (by Company), January 2022-December 2024